Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE GALENA BIOPHARMA, INC. SECURITIES LITIGATION
Case Number:
2:17-cv-00929
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Carella Byrne
- Faruqi & Faruqi
- Goodwin Procter
- Greenberg Traurig
- Hughes Hubbard
- Kantrowitz Goldhamer
- Paul Hastings
- Riley Safer
Companies
Sectors & Industries:
-
September 16, 2021
Galena Settles Investors' Revived Opioid Row For $1.6M
A group of investors has urged a New Jersey federal judge to grant preliminary approval to a $1.6 million settlement with Galena Biopharma Inc. to resolve allegations the company caused a stock drop with purported misrepresentations regarding its fentanyl-based drug Abstral.
-
November 13, 2019
Galena Again Beats Investors' 'Shotgun' Opioid Claims Suit
The former Galena Biopharma Inc. has defeated for a second time a proposed class action over alleged misrepresentations regarding its fentanyl-based drug Abstral, with a New Jersey federal judge blasting investors' "shotgun approach" in presenting their securities fraud claims.
-
August 21, 2018
Galena Investors' Stock-Drop Suit Gets Axed, For Now
A New Jersey federal judge on Tuesday tossed a putative securities class action that claims Galena Biopharma Inc. and its top brass hid from investors that revenues from the company's pain drug Abstral were driven by an illegal off-label prescription business, finding the investors' liability theory unclear but giving them a chance to fix the issue.